Fortress Biotech Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Fortress Biotech will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, with key proposals including director elections and equity plan amendments.</b>

AI Summary

Fortress Biotech, Inc. (FBIOP) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Annual Meeting scheduled for May 23, 2024, conducted virtually. Stockholders to elect eight directors for a one-year term. Proposal to ratify KPMG LLP as independent auditor for fiscal year ending December 31, 2024. Proposes to amend 2013 Stock Incentive Plan to increase share availability by 10,000,000. Proposes to amend 2012 Employee Stock Purchase Plan to increase share availability by 1,000,000.

Why It Matters

For investors and stakeholders tracking Fortress Biotech, Inc., this filing contains several important signals. The meeting will address critical governance matters, including the election of directors and the ratification of the independent auditor, which are standard but essential for corporate oversight. Proposed amendments to stock incentive and employee stock purchase plans aim to provide future equity compensation and incentivize employees, potentially impacting share dilution and future stock performance.

Risk Assessment

Risk Level: low — Fortress Biotech, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.

Analyst Insight

Review the proposals for director elections and equity plan amendments to understand potential impacts on share structure and executive compensation.

Key Numbers

• 2024-05-23 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• 8 — Directors to be Elected (Number of directors to be elected at the meeting)
• 2024 — Fiscal Year for Auditor Ratification (Fiscal year for which KPMG LLP is proposed to be ratified as auditor)
• 10,000,000 — Additional Shares for Stock Incentive Plan (Increase in shares issuable under the 2013 Stock Incentive Plan)
• 1,000,000 — Additional Shares for Employee Stock Purchase Plan (Increase in shares issuable under the 2012 Employee Stock Purchase Plan)

Key Players & Entities

• Fortress Biotech, Inc. (company) — Registrant
• May 23, 2024 (date) — Annual Meeting date
• KPMG LLP (company) — independent registered public accounting firm
• December 31, 2024 (date) — fiscal year end
• 2013 Stock Incentive Plan (other) — plan to be amended
• 10,000,000 (dollar_amount) — shares to be added to stock incentive plan
• 2012 Employee Stock Purchase Plan (other) — plan to be amended
• 1,000,000 (dollar_amount) — shares to be added to employee stock purchase plan

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC regulations regarding proxy solicitations and annual meetings, including timely filing and accurate disclosure.
• Equity Plan Dilution [medium — financial]: Increasing the number of shares available under stock incentive and purchase plans could lead to dilution of existing shareholders' equity.
• Virtual Meeting Logistics [low — operational]: Conducting a fully virtual meeting requires robust technology and clear communication to ensure all stockholders can participate effectively.

Key Dates

• 2024-05-23: Annual Meeting of Stockholders — Key date for voting on proposals and electing directors.

Glossary

Proxy Statement

A document filed with the SEC that provides information to shareholders about matters to be voted on at a company's annual or special meeting. (Provides essential details about the proposals being voted on at the Annual Meeting.)

Filing Documents

• tmb-20240523xdef14a.htm (DEF 14A) — 1069KB
• tmb-20240523xdef14a_a001.jpg (GRAPHIC) — 6KB
• tmb-20240523xdef14a_a008.jpg (GRAPHIC) — 52KB
• tmb-20240523xdef14a_a009.jpg (GRAPHIC) — 54KB
• tmb-20240523xdef14a_bg001.jpg (GRAPHIC) — 154KB
• tmb-20240523xdef14a_bg002.jpg (GRAPHIC) — 102KB
• 0001558370-24-004791.txt (&nbsp;) — 1579KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 18 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END 21 EQUITY COMPENSATION PLAN INFORMATION 23 PAY VERSUS PERFORMANCE 23 DIRECTOR COMPENSATION 23 DELINQUENT SECTION 16(A) BENEFICIAL OWNERSHIP REPORTS 27 RELATED-PERSON TRANSACTIONS 27 STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS 33 PROPOSAL ONE: ELECTION OF DIRECTORS NOMINEES 34 PROPOSAL TWO: RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 35 PROPOSAL THREE: AMENDMENT TO THE COMPANY'S 2013 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER AND INCREASE THE ANNUAL SHARE LIMIT FOR PARTICIPANTS PURSUANT TO GRANTS OF STOCK OPTIONS AND STOCK APPRECIATION RIGHTS 36 PROPOSAL FOUR: AMENDMENT TO THE COMPANY'S 2012 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER AND INCREASE THE NUMBER OF SHARES ELIGIBLE FOR PURCHASE DURING AN "OFFERING" 43 IVE PROPOSAL FIVE: AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED LONG TERM INCENTIVE PLAN TO EXTEND THE TERM OF THE PLAN TO JULY 15, 2035 AND TO MAKE CERTAIN RELATED CHANGES 47 Table of Contents QUESTIONS AND ANSWERS Q. Why did I receive an "Important Notice Regarding the Availability of Proxy Materials"? A. In accordance with Securities and Exchange Commission (the "SEC") rules, instead of mailing a printed copy of our proxy materials, we may send an "Important Notice Regarding the Availability of Proxy Materials" to stockholders. All stockholders will have the ability to access the proxy materials on the website referred to in the notice or to request a printed set of these materials at no charge. You will not receive a printed copy of the proxy materials unless you specifically request one from us. Instead, the notice instructs you as to how you may access and review all of the important information co

View Full Filing

View this DEF 14A filing on SEC EDGAR